Alnylam Pharmaceuticals News and Activities
Presence
Alnylam Pharmaceuticals develops RNA-based medicines for rare and common diseases. Its products and services include genetic disease treatments and drug research for patients, healthcare providers, and pharmaceutical partners.
Alnylam Pharmaceuticals products and services overview:
- RNA therapies
- Rare disease drugs
- Cardiometabolic treatments
- Genetic medicines
- Drug discovery
Revenue: ~$2 billion
Employees: 2,100
Headquarters: Cambridge, United States (USA)
Alnylam Pharmaceuticals is one of the...
Alnylam Pharmaceuticals is a company listed under the stock ticker ALNY (US).
Executives
View the org chart displaying its 36 main executives
Most searched biographies at Alnylam Pharmaceuticals
- Yvonne Greenstreet, Chief Executive Officer and Director
- Amy Schulman, Chairman of the Board
- Benjamin Cravatt, Director
Popular executive movements at Alnylam Pharmaceuticals
- Benjamin Cravatt will join the company as Director on Jun. 1, 2026 (posted on May 28 2026).
- Toby Ferguson has joined the company as Senior Vice President, Neuroscience Therapeutic (posted on April 22 2026).
- Michael Bonney, Director, has left the company (posted on December 3 2025).
Click here to view some more movements at Alnylam Pharmaceuticals
Create your alert
to follow the executive moves at Alnylam Pharmaceuticals.
Biotechnology
Alnylam Pharmaceuticals has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Alnylam Pharmaceuticals
- Alnylam Issues 2025 Corporate Responsibility Report
- New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutris
- Alnylam to Webcast Presentations at Upcoming Investor Conferences
- Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
- Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran i
- Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
- New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran fo
- Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the Americ
- Alnylam to Webcast TTR Investor Webinar
- Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference
- View more press releases Close
Social media about Alnylam Pharmaceuticals
- Alnylam Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Alnylam Pharmaceuticals on LinkedIn, X (Twitter) & YouTube
